Article ID Journal Published Year Pages File Type
3104256 Burns 2015 6 Pages PDF
Abstract

•Human amnion preserved in glycerol 98% is safer regarding the risk of disease transmission.•Clinical efficacy of using human amnion preserved in glycerol 98% has not been tested.•We compared it as dressing of skin graft donor site with conventional method.•We found human amnion preserved in glycerol 98% more effective in promoting healing.•We found human amnion preserved in glycerol 98% more effective in pain control.

IntroductionPreservation of human amniotic membrane (HAM) in glycerol 85% has been used clinically but the use of glycerol 98% can give the maximum virucidal activity and increases the safety of HAM.ObjectiveTo determine the degree of clinical efficacy of HAM preserved in glycerol 98% as a biological dressing in management of donor site of split thickness skin graft (STSG).Patients and methods40 subjects were enrolled in this randomized, controlled study conducted in Al-Azhar University Hospitals from August 2013 to June 2014. We compared HAM preserved in glycerol 98% to vaseline gauze. Patients were randomly allocated to STSG donor site dressing with one of these materials. Outcome measures included pain scores at postoperative days 2, 6 and 10, time to re-epithelialization, and incidence of infection.ResultsBoth groups were homogenous regarding age, gender, cause of burn and size. The HAM group showed significantly less pain on postoperative days 2 and 6 (4 and 2.7 vs. 5.6 and 4.2 respectively with p value <0.05). Shorter time to re-epithelialization was also found in the HAM group (11.7 vs. 15.4 with p value <0.05). No significant difference was found between both groups in the incidence of infection.ConclusionHAM preserved in glycerol 98% is clinically effective as a biological dressing. The higher glycerol concentration increases the safety of HAM with retaining the clinical effect at the same time.

Related Topics
Health Sciences Medicine and Dentistry Critical Care and Intensive Care Medicine
Authors
, , , , , , , , ,